Antidepressant use in pregnancy associated with anxiety symptoms in 3-year-olds

Posted on April 22, 2015

A new study by researchers from the Norwegian Institute of Public Health (NIPH), the University of Oslo and the Hospital for Sick Children in Toronto, Canada shows the importance of considering the potential long-term effects on child development when addressing the safety of antidepressant use during pregnancy.

The effect of antidepressant exposure on anxiety symptoms was controlled for important potential confounders such as genetic effects, family environment and variation in symptoms of maternal depression between the woman’s pregnancies.

The effect of prenatal antidepressant exposure was specific to anxiety, and not associated with emotional reactivity, somatic complaints, sleep problems, attention problems or aggression in the siblings.

The study also found evidence that maternal depression was independently associated with child behaviour problems. There was however a stronger association between antidepressant exposure and child behaviour problems than between depression and child behaviour problems.

"These findings are in line with previous research, but to my knowledge this is the first study that has taken into account that depression and emotional problems have a genetic component. Siblings share on average 50 per cent of their genes. By studying the effect of prenatal antidepressant use and maternal depression in sibling clusters, we can control for a large proportion of the genetic influence," says Ragnhild Eek Brandlistuen, researcher and lead author of the study.

The results of this study indicate that both antidepressant use and depression during pregnancy can have a negative effect on the child regardless of genetic or environmental factors that the child shares with its siblings.

The mechanism behind this effect is primarily that the antidepressant drugs, particularly of the type SSRI, alter the serotonin levels in the brain of the foetus. This can influence the foetus' brain development.

Maternal depression also alters the serotonin levels in the foetus, and increases the level of the stress hormone cortisol. Cortisol can also influence the foetus' brain development.

Potential long-term effects of medication and untreated maternal mental disease should be considered when assessing the benefits and risks of antidepressant use during pregnancy.

"Taken together, these findings form a strong basis for identifying and implementing non-medical interventions to reduce antenatal depression whenever possible," says Brandlistuen.

An example of effective non-medical treatment is cognitive behavioural therapy (CBT).

However, in the case of severe depression, medical treatment may be necessary. The potential risks observed in the child must be balanced against the benefit of the mother remaining stable in her condition for both mother and baby.


Category(s):Child Development, Pregnancy & Birthing

Source material from Norwegian Institute of Public Health


Mental Health News